Export Import Guru

Exim SEO is an initiative by Barai Overseas to help its Client to get International reach in Export Business

Categories

Pharma Export to Australia from India: TGA, PBS & Startup Guide

How to Export Pharmaceutical Products from India to Australia: Market Opportunities, TGA Registration, PBS Pricing and Merchant Export Strategy

Australia is one of the most attractive regulated pharmaceutical markets for Indian exporters.

However, many Indian startup merchant exporters avoid this market because they believe that pharmaceutical registration, government regulations and international competition make exporting almost impossible.

The reality is more interesting.

Australia has an established pharmaceutical market, regular demand for essential medicines and a government-supported medicine subsidy system.

At the same time, the country has strict regulatory requirements, and Indian exporters must understand how to enter the market legally.

The opportunity is not simply to identify a medicine with high demand and ship it from India.

The real opportunity is to find a suitable pharmaceutical product, identify a qualified Australian business partner, understand the registration requirements and develop a commercially viable supply arrangement.

For a startup merchant exporter, this may sound complicated.

However, the process becomes easier to understand when we divide it into practical steps.

In this guide, we will explore Australia's pharmaceutical market, India's export performance, the role of the Therapeutic Goods Administration (TGA), the Australian Register of Therapeutic Goods (ARTG), the Pharmaceutical Benefits Scheme (PBS), Australian sponsors, and practical strategies for entering this market without owning a manufacturing factory.

Why Australia Is an Important Pharmaceutical Export Market for India

India is already an established supplier of pharmaceutical products to Australia.

According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India's pharmaceutical exports to Australia reached approximately USD 469.76 million during the financial year 2024–25.

This represented an increase of approximately 3.39% compared with the previous financial year.

Australia ranked as India's 12th-largest pharmaceutical export destination in that year and accounted for approximately 1.54% of India's total pharmaceutical exports.

These figures are important for Indian entrepreneurs.

They show that pharmaceutical trade between India and Australia is not a new or completely unexplored opportunity.

There is already an established supply relationship.

However, the presence of substantial exports does not automatically mean that every Indian startup can immediately begin supplying medicines.

A large portion of international pharmaceutical trade is managed through established manufacturers, registered products and regulated distribution arrangements.

A startup must understand how to participate in this existing business environment.

What Makes Australia's Pharmaceutical Market Attractive?

Australia has a developed healthcare system and a structured process for supplying medicines.

Several factors contribute to the country's continuing pharmaceutical requirements.

Ageing Population

As populations age, healthcare systems need to manage more age-related medical conditions.

Older patients may require medicines for long-term conditions such as cardiovascular disease, diabetes and other health problems.

This can create continuing demand for certain pharmaceutical categories.

Chronic Disease Management

Many chronic health conditions require regular treatment and monitoring.

For example, patients with hypertension, diabetes or certain respiratory conditions may need ongoing medication according to their doctor's treatment plan.

This creates recurring healthcare requirements.

However, the actual commercial demand for a specific medicine depends on its approved indications, prescribing patterns, competing products and market access.

Developed Pharmacy and Healthcare Distribution Systems

Australia has established networks of pharmacies, wholesalers, hospitals and healthcare suppliers.

These organizations require reliable medicine availability and properly regulated supply chains.

For Indian manufacturers and exporters, supplying through qualified Australian partners can create opportunities to participate in these distribution systems.

Government Support for Medicine Affordability

One of the most important features of Australia's pharmaceutical market is the Pharmaceutical Benefits Scheme.

The PBS helps eligible patients obtain many prescribed medicines at subsidised prices.

This is particularly relevant for exporters researching generic medicines and products used in the management of ongoing medical conditions.

Understanding the PBS is essential before evaluating the commercial potential of Australia's pharmaceutical market.

What Is the Pharmaceutical Benefits Scheme (PBS)?

PBS stands for Pharmaceutical Benefits Scheme.

It is an Australian Government programme that subsidises the cost of many medicines for eligible patients.

Let us understand this through a simple example.

Imagine that a medicine has an eligible full supply price under the PBS.

A qualifying patient may pay only the applicable patient contribution, while the government subsidises the remaining eligible amount according to PBS rules.

The patient does not necessarily pay the entire unsubsidised price.

This helps improve access to medicines.

For pharmaceutical companies, PBS listing can be commercially important because it affects reimbursement and patient affordability.

However, a medicine being approved by the TGA does not automatically mean that it is included in the PBS.

The two systems perform different functions.

TGA regulates whether a therapeutic product can legally be supplied in Australia.

PBS determines whether a medicine is subsidised for eligible patients and under what conditions.

This distinction is extremely important for Indian exporters.

How the PBS Can Influence Demand for Generic Medicines

Generic medicines contain the same relevant active ingredient as an established reference medicine and must meet applicable regulatory requirements.

For products requiring bioequivalence, the manufacturer must provide appropriate evidence demonstrating that the generic product meets the relevant standards.

When suitable generic medicines enter a market, they may create additional competition.

The PBS system includes mechanisms affecting medicine prices and subsidies.

This means pharmaceutical distributors and sponsors must consider both regulatory approval and PBS commercial conditions.

For an Indian exporter, a generic medicine may be commercially attractive if it meets the Australian requirements and can be supplied reliably at a competitive price.

However, PBS listing does not guarantee a particular sales volume or profit margin.

Price reductions, existing brand competition, distribution agreements and government reimbursement conditions can affect profitability.

Therefore, startups should study the actual medicine and its PBS position before estimating business potential.

How Indian Exporters Can Research PBS Medicine Prices

One of the biggest advantages for startup exporters is that Australia provides official public resources for pharmaceutical market research.

The PBS website allows users to search for medicines included in the scheme.

An exporter can use this information to understand existing subsidised products and relevant pricing arrangements.

Start by visiting:

https://www.pbs.gov.au/

Search for the active ingredient or medicine you want to investigate.

For example, if you are researching a generic medicine used in diabetes management, enter the relevant active ingredient.

Study the available product information, strengths, pack sizes, brands and applicable restrictions.

Review the relevant pricing information shown in the PBS Schedule.

However, do not confuse the patient contribution, government reimbursement amount or published PBS price with the amount an Indian exporter will receive from an Australian distributor.

These are different commercial figures.

The actual export selling price must be negotiated with the buyer.

Your manufacturer quotation, import costs, distribution arrangements and the sponsor's commercial requirements will influence the transaction.

For startups, the PBS database is a useful research tool, not a direct quotation platform.

Understanding Australia's Main Pharmaceutical Regulatory Authority

The Therapeutic Goods Administration, commonly called the TGA, regulates medicines and other therapeutic goods in Australia.

Its responsibilities include evaluating appropriate product information, administering market-authorisation requirements and monitoring products supplied in the country.

For a new Indian exporter, understanding the TGA is one of the first steps toward entering Australia's pharmaceutical market.

A medicine that is legally manufactured and sold in India cannot automatically be shipped to Australia for ordinary commercial sale.

In general, it must be included in the Australian Register of Therapeutic Goods unless a specific exemption, approval or other lawful pathway applies.

This requirement is central to the Australian pharmaceutical supply system.

What Is the Australian Register of Therapeutic Goods (ARTG)?

ARTG stands for Australian Register of Therapeutic Goods.

It is the official Australian register containing information about therapeutic goods authorised for supply.

The register includes relevant details of medicines and other regulated products.

For a pharmaceutical exporter, the ARTG is particularly useful because it helps identify products already present in the Australian market.

The public register can provide information such as the product name, active ingredients, sponsor, manufacturer details and registration or listing status.

Let us understand why this matters.

Suppose you are planning to export a generic medicine from India.

Before contacting Australian buyers, you can search the ARTG to understand which products with the relevant ingredient and strength are already authorised.

You may identify established brands, competing products and the Australian companies responsible for those entries.

This provides useful information for market research and buyer identification.

It can also help you understand whether a product category already has multiple registered suppliers.

How to Search the ARTG Step by Step

First, visit the official TGA website:

https://www.tga.gov.au/

Open the section for the Australian Register of Therapeutic Goods.

You can use the public ARTG search to look for relevant products.

For example, suppose you are researching a particular oral prescription medicine.

Search using its active ingredient.

Then review the available results.

Check the medicine's strength, dosage form, product name and sponsor details.

Where available, examine the Product Information and other public documents.

These records can help you prepare a list of established market participants.

However, an ARTG listing does not disclose complete sales volumes or confidential supply contracts.

The register is useful for understanding market authorisation and identifying relevant companies, but it is not proof that a particular brand is selling successfully.

This is where the PBS database and direct market research become valuable.

Understanding the Difference Between AUST R, AUST L and AUST L(A)

Australian medicines do not all follow the same regulatory pathway.

An exporter must understand the differences.

AUST R – Registered Medicines

Registered medicines include all prescription medicines and many over-the-counter medicines.

These products undergo the applicable TGA evaluation of quality, safety and efficacy.

Generic prescription medicines are generally part of this registered-medicine framework.

AUST L – Listed Medicines

Listed medicines are lower-risk products that use permitted ingredients and limited approved types of therapeutic claims.

Many complementary medicines fall within this category.

They are included after the sponsor certifies compliance with the applicable requirements, without the same individual pre-market efficacy evaluation as registered medicines.

AUST L(A) – Assessed Listed Medicines

These are listed medicines for which the TGA has assessed supporting evidence for the relevant efficacy claims, along with the applicable regulatory requirements.

An important lesson for startups is that an OTC product is not automatically a listed medicine.

Many ordinary OTC medicines are registered medicines and require the relevant evaluation.

Therefore, always establish the correct regulatory pathway before selecting a product.

Why Pharmaceutical Registration Is a Challenge for Indian Exporters

Australia is an attractive market because it has an established healthcare system and a structured pharmaceutical supply chain.

However, gaining market access can require substantial preparation.

For example, a generic prescription medicine may require a suitable regulatory dossier.

This can include information concerning the active ingredient, formulation, manufacturing process, quality specifications, stability and appropriate bioequivalence evidence.

The product must also meet the applicable requirements for manufacturing quality and labelling.

The Australian sponsor is responsible for making the relevant submission to the TGA.

The application process may involve evaluation fees and other regulatory expenses.

These requirements can create barriers for small exporters who do not have sufficient technical documentation or a qualified manufacturing partner.

However, there is a practical way for merchant exporters to approach this situation.

Instead of independently building a complete registration operation in Australia, they can explore partnerships with suitable Australian sponsors and distributors.

This brings us to one of the most important parts of the business model.

Who Is an Australian Sponsor?

An Australian sponsor is a person or organization that takes the relevant legal responsibility for therapeutic goods supplied in Australia under the Australian regulatory framework.

A sponsor generally must be an Australian resident or a suitably incorporated business carrying on business in Australia.

For medicines requiring ARTG inclusion, the sponsor is responsible for the relevant registration or listing application.

The sponsor also has ongoing regulatory obligations.

These may involve maintaining appropriate records, overseeing product compliance, managing relevant safety reporting obligations and coordinating necessary regulatory actions.

For an overseas pharmaceutical company, an Australian sponsor can provide the local regulatory role needed for lawful commercial supply.

However, an important point must be understood.

An Australian sponsor is not simply a consultant who completes paperwork and then disappears.

The sponsor holds significant legal responsibilities connected with the product.

Therefore, selecting a sponsor requires careful evaluation.

What Is the Difference Between an Australian Sponsor and a Distributor?

This is a common source of confusion among new exporters.

A sponsor is a regulatory role.

A distributor is a commercial supply-chain role.

A single Australian company may perform both roles.

For example, an Australian pharmaceutical distributor may already have the relevant regulatory capabilities and may also be willing to act as the sponsor for a product.

In another arrangement, a separate Australian sponsor may be responsible for regulatory matters while another business manages distribution.

These arrangements must be clearly defined in contracts.

A sponsor does not automatically guarantee sales, buyer introductions or annual purchase orders.

Similarly, a distributor is not automatically authorised to act as the sponsor for an unregistered product.

The entrepreneur should understand exactly which responsibilities each partner will accept.

How an Indian Merchant Exporter Can Work with an Australian Sponsor

Consider a practical example.

An Indian merchant exporter identifies a generic medicine that may have commercial potential in Australia.

The exporter works with a qualified Indian manufacturer capable of supplying the required formulation and technical documentation.

The exporter then approaches a suitable Australian pharmaceutical business.

The Australian company reviews the product's commercial potential and regulatory requirements.

If both parties see a genuine business opportunity, they may discuss an agreement.

The Australian sponsor may coordinate the applicable TGA registration or market-authorisation process.

The Indian manufacturer provides the required technical and manufacturing documentation.

The Indian merchant exporter coordinates the sourcing arrangement, commercial supply and communication between the parties.

Once the necessary regulatory approvals are obtained and commercial arrangements are finalized, the product may be supplied according to the approved conditions.

This is one possible business structure.

It is not the only structure, and approval is never guaranteed.

The responsibilities must be properly documented before the parties begin making financial commitments.

Who Pays the TGA Registration and Compliance Expenses?

One important question for startups is:

"Do Indian exporters need to pay all the registration expenses themselves?"

Not necessarily.

The financial responsibilities can be negotiated between the parties.

For example, an Australian sponsor may be willing to invest in registering a product if it has strong commercial prospects.

An Indian manufacturer may agree to contribute toward product registration to enter a new international market.

A merchant exporter may also participate in commercial or regulatory-related costs under an agreed arrangement.

Another possibility is that the Australian buyer funds certain market-entry activities in exchange for suitable distribution rights or commercial terms.

However, none of these arrangements is automatic.

The sponsor is not legally required to fund the Indian exporter's market-entry costs.

The final arrangement depends on negotiation, expected sales, product value, regulatory complexity and the business relationship.

For startups, cost sharing can reduce initial financial pressure, but it may also reduce future earnings or create long-term contractual commitments.

Therefore, every expense-sharing arrangement should be evaluated carefully.

Can an Australian Sponsor Ask for a Percentage of the Business?

Yes, commercial partners may negotiate compensation through service fees, distribution margins, profit-sharing arrangements or other contractual structures.

However, there is no universal requirement that an Australian sponsor must receive a fixed percentage of the exporter's profits.

Suppose an Australian company agrees to handle regulatory activities and also becomes the exclusive distributor.

The parties might negotiate the supply price, expected volumes, minimum purchase commitments and responsibilities for registration expenses.

Alternatively, a separate regulatory sponsor may charge agreed service fees.

Both arrangements have different commercial implications.

For a startup exporter, the important question is not simply:

"How much does the sponsor charge?"

A better question is:

"What services, responsibilities and market access will the sponsor provide in exchange for the agreed compensation?"

Before signing a contract, discuss the sponsor's duties, ownership and control of the ARTG entry, commercial rights, exclusivity, supply commitments, liability arrangements and what happens if the relationship ends.

These details can significantly affect your long-term business.

Why ARTG Ownership and Sponsor Control Matter

Imagine that you spend considerable time and money developing an Australian market for a product.

You identify a manufacturer, negotiate pricing and help arrange regulatory documentation.

The product is then included in the ARTG under the Australian sponsor.

After two years, the business relationship becomes difficult.

What happens to your product's market access?

Can you immediately replace the sponsor?

Can you continue supplying the same product through another distributor?

These questions should be considered before signing the original agreement.

The regulatory entry is linked to the sponsor and the approved product particulars.

Changing the sponsor or relevant product details may involve formal regulatory procedures.

A merchant exporter should not assume that registration can be transferred freely or that the exporter automatically owns the ARTG entry.

A properly prepared commercial agreement should address the consequences of termination, changes in supply arrangements, regulatory cooperation and relevant intellectual property rights.

Qualified Australian legal and regulatory advice is useful when structuring such agreements.

Why Indian Manufacturer Selection Is Critical

A successful Australian market-entry strategy begins with the right manufacturing partner.

It is not enough to find an Indian factory offering an attractive price.

The manufacturer must be capable of meeting the relevant Australian requirements.

For example, the supplier should be able to provide appropriate documentation about manufacturing quality, product specifications and stability.

If a generic prescription medicine is involved, suitable bioequivalence information may also be required.

The manufacturing site may need applicable TGA Good Manufacturing Practice clearance or certification.

This brings us to another important term.

What Is TGA GMP Clearance?

GMP stands for Good Manufacturing Practice.

GMP requirements help ensure that pharmaceutical products are consistently manufactured and controlled according to appropriate quality standards.

For overseas manufacturers supplying Australia, the TGA may require GMP clearance or certification for relevant manufacturing sites.

Importantly, an Indian manufacturing licence or GMP certificate does not automatically replace the specific Australian requirement.

The sponsor must establish that the relevant overseas manufacturing arrangements meet the TGA's applicable expectations.

Depending on circumstances, GMP clearance may involve recognized evidence, inspection reliance or other TGA procedures.

The exact pathway depends on the manufacturer, evidence and product.

For a merchant exporter, this means the manufacturer's Australian regulatory readiness should be checked early.

A supplier with previous experience supplying registered medicines to Australia may already understand many of these requirements.

However, the exporter must still verify whether the existing approvals and manufacturing arrangements cover the particular product being proposed.

Why Generic Prescription Medicines Need Careful Evaluation

Generic medicines can provide opportunities for Indian manufacturers.

However, Australia does not approve a generic product simply because it contains the same active ingredient as an existing medicine.

The applicant must satisfy applicable quality and regulatory requirements.

Bioequivalence evidence may be necessary to demonstrate that the proposed generic is appropriately comparable with the reference medicine.

The TGA's guidance generally expects bioequivalence studies for generic applications to use an appropriate reference product sourced from Australia, subject to the relevant requirements and exceptions.

This is an important technical point for startups.

A manufacturer may already have registered a similar generic medicine in another country.

But the same dossier may not automatically satisfy the Australian pathway.

Therefore, before contacting Australian sponsors, ask the Indian manufacturer whether it has suitable Australian registration experience and the required regulatory data.

Without this information, even a commercially attractive product may be difficult to introduce.

What Products Should Indian Startups Research for Australia?

The video identifies continuing healthcare demand linked to conditions such as diabetes, cardiovascular disease and respiratory disorders.

These are reasonable therapeutic areas to study because they involve substantial ongoing healthcare needs.

For example, startups may research relevant generic prescription medicines used in established treatment programmes.

However, the first product should not be selected simply because many patients have that disease.

Instead, the exporter should identify a specific formulation, strength and dosage form.

Then examine its ARTG status, PBS information, competing brands, supplier availability and actual importer interest.

For example, two medicines in the same therapeutic category may have very different registration requirements and commercial opportunities.

A common generic product can still be commercially attractive if the exporter can arrange reliable supply at a competitive cost.

But strong competition and limited margins can make the same product unattractive for another startup.

The correct decision depends on the complete commercial situation.

How to Identify Competitors Using ARTG

Imagine you are researching a generic prescription medicine.

You already know that an Indian manufacturer can produce the required formulation.

Now you want to understand the existing Australian market.

Start by searching the active ingredient in the ARTG.

Identify the registered brands and available sponsor details.

Check the dosage strengths and other relevant product particulars.

Where possible, examine the listed manufacturers.

Prepare a simple competitor research sheet.

Record the active ingredient, brand name, strength, dosage form, sponsor and ARTG number.

This information can help identify companies already operating within the product category.

However, the register does not tell you whether every product is currently profitable or how much inventory each sponsor purchases.

For that information, you will need further commercial research and buyer discussions.

How to Identify Potential Buyers from ARTG Research

The ARTG can also help exporters identify relevant Australian companies.

For example, suppose several pharmaceutical companies appear as sponsors of products in your chosen therapeutic category.

These companies may be worth researching.

Visit their official websites.

Study their product portfolios.

Understand whether they manufacture, import, distribute or sponsor medicines.

Then determine whether your proposed product would fit their business.

However, do not assume that every sponsor is looking for another Indian supplier.

An established company may already have long-term agreements with existing manufacturers.

The purpose of the research is to identify potentially relevant businesses for professional outreach.

A startup should focus on a small, well-researched group of prospective buyers rather than sending the same generic email to hundreds of companies.

How to Use PBS Data for Commercial Research

Once you identify the competitor products in ARTG, study relevant PBS listings.

For the selected medicine, review the strengths, brand entries, applicable restrictions and pricing information.

Pay attention to whether the product is subsidised and what the published schedule tells you about its market position.

You should also understand that PBS prices may change.

Generic competition, price disclosure mechanisms and government pricing arrangements can influence the commercial environment.

For example, a product may initially appear attractive because the published reimbursement-related price is relatively high.

However, future pricing changes may reduce the available commercial margin.

Therefore, the exporter must evaluate the sustainability of the business.

The PBS is a starting point for commercial research.

It is not a substitute for obtaining an actual purchase price, volume estimate and distribution plan from an Australian buyer.

Can Medicine Shortages Create Opportunities for Indian Exporters?

Another useful research area is Australia's official medicine shortage information.

The TGA publishes information about reportable medicine shortages and supply disruptions.

For example, shortages may result from manufacturing delays, unexpected demand, supply-chain problems or discontinuation.

This can help entrepreneurs identify areas where reliable alternative supply may be commercially relevant.

However, a shortage does not automatically authorize an Indian exporter to supply an unregistered medicine.

Australia has specific pathways for accessing certain unapproved medicines in exceptional circumstances.

For example, section 19A arrangements may permit approved overseas alternatives during particular shortage situations.

These are controlled regulatory pathways, not general exemptions for new exporters.

A merchant exporter should work with an appropriately authorised Australian sponsor or supplier and follow the relevant regulatory procedure.

Shortage research is valuable for understanding supply-chain problems, but it should not be treated as permission to bypass the TGA.

How to Convince an Australian Pharmaceutical Buyer

Australian pharmaceutical companies are familiar with international sourcing and regulated supply chains.

A generic company introduction may not be enough to generate interest.

Suppose you write:

"We are a leading pharmaceutical exporter from India. We supply high-quality medicines at the best prices."

This tells the buyer very little.

A more useful approach is to present the specific product, manufacturer qualifications and commercial value.

For example, you may explain that your company is working with an Indian manufacturer capable of supplying a particular generic formulation.

You can mention the product's available technical documentation, the manufacturer's relevant regulatory experience and the possibility of discussing suitable commercial arrangements.

If the buyer already has the product, your next question may concern sourcing diversification or supply reliability.

The goal is not to suggest that the existing supplier is poor.

The goal is to determine whether your product could provide a useful additional supply option.

A Practical Buyer Communication Example

Subject: India–Australia Pharmaceutical Supply Discussion – Generic Product Sourcing

Dear Procurement Team,

Greetings from Barai Overseas, India.

We are exploring opportunities to support Australian pharmaceutical companies with selected generic medicines sourced through qualified Indian manufacturers.

Our focus is on understanding the exact product requirements, available technical documentation, manufacturing quality and long-term supply needs of our international partners.

We would be interested in learning whether your organization is currently evaluating alternative suppliers or additional sourcing arrangements for any generic pharmaceutical categories.

Based on the specific product requirement, we can coordinate relevant manufacturer information, technical documentation, available product details and commercial quotations for your review.

We also understand the importance of the TGA registration process and the role of an Australian sponsor in bringing pharmaceutical products to market.

We would welcome the opportunity to understand your current procurement requirements and explore whether a suitable supply arrangement is possible.

Best regards,

Barai Overseas

https://www.exportimport.guru/

This is an introductory business communication, not a claim that a particular product already has Australian market authorization.

Any product-specific regulatory or clinical claims should be verified before being included in commercial correspondence.

Why an Annual Volume Commitment Matters

One of the most important business lessons in the video is the need to discuss expected purchase volumes before investing heavily in market entry.

For example, suppose an Indian exporter and Australian sponsor are considering registration of a generic medicine.

The parties estimate significant costs for regulatory work, documentation, testing and market preparation.

Before agreeing to these expenses, the exporter should ask:

How many units might the Australian partner realistically purchase each year?

What is the expected minimum order quantity?

Will the distributor provide a forecast?

Is there an opportunity for an initial trial order after authorization?

What is the expected purchase price?

Will the buyer agree to minimum purchase commitments?

Who will bear the registration expenses if commercial sales are lower than expected?

These questions help the entrepreneur understand whether the proposed business is commercially realistic.

However, a sales forecast is not the same as a legally binding purchase commitment.

A sponsor or distributor may estimate annual demand without guaranteeing it.

If the business requires guaranteed minimum purchases, these should be discussed and documented through appropriate contractual arrangements.

How to Negotiate Registration Cost Sharing

Imagine that an Australian pharmaceutical distributor identifies commercial potential in a generic medicine.

The distributor requires a reliable Indian manufacturer.

You identify a qualified manufacturer with suitable documentation and pricing.

Now all parties must decide how to proceed.

One possibility is that the Australian company handles and funds the market-authorisation process.

Another is that the manufacturer and sponsor share certain expenses.

The merchant exporter may receive an agreed sourcing or trading margin on future orders.

Alternatively, the parties may negotiate a longer-term supply arrangement that reflects their respective contributions.

The important point is that commercial value should be clearly understood.

If the Australian partner is investing in registration, it may request exclusive distribution rights or certain commercial protections.

The Indian manufacturer may seek minimum order commitments before supporting the project.

The merchant exporter should protect its legitimate sourcing role through appropriate agreements.

However, exclusivity, profit sharing and minimum purchase clauses must be carefully negotiated.

A startup should not accept open-ended financial liabilities or guarantee sales that it cannot control.

What Should Be Included in a Sponsor or Distributor Agreement?

Before making financial commitments, the parties should clearly define their relationship.

Important matters to discuss include:

Product identification and specifications.
Manufacturer details and regulatory responsibilities.
Australian sponsor responsibilities.
Ownership and control of the ARTG entry.
Registration and evaluation expenses.
Ongoing regulatory charges.
Distribution territory and exclusivity.
Product pricing and payment arrangements.
Annual forecasts and minimum order commitments.
Supply lead times and delivery conditions.
Product complaints, recalls and pharmacovigilance responsibilities.
Product liability and insurance.
Intellectual property and confidentiality.
Termination and transition arrangements.
Responsibilities if market authorization is delayed or refused.

A qualified Australian legal and regulatory professional should review agreements involving TGA obligations.

These provisions can help prevent disputes after the business begins.

A Practical Export Costing Example

Suppose an Indian merchant exporter identifies a generic medicine with potential Australian demand.

The exporter obtains an indicative manufacturer quotation.

However, the factory price alone does not establish the complete export cost.

The exporter may need to account for:

Product procurement.

Packaging and labelling according to approved specifications.

Quality testing and documentation.

Inland transportation in India.

Export customs procedures.

International freight and insurance, where applicable.

Banking and payment expenses.

Regulatory or registration contributions agreed under the contract.

Storage and handling requirements.

Product-specific technical and compliance expenses.

In addition, the Australian sponsor or distributor may incur local costs for registration, customs, storage, distribution, regulatory maintenance and other activities.

These costs affect the commercial price that the buyer can pay.

Therefore, the Indian exporter's quotation and the Australian retail or PBS-related price should not be directly compared without understanding the complete supply chain.

The business is viable only when the agreed transaction generates an acceptable margin after all relevant expenses and risks.

The Three Main Market-Entry Strategies for Indian Merchant Exporters

A startup can consider three broad commercial approaches.

Strategy 1: Supply Through an Established Australian Sponsor

Under this approach, the exporter identifies a suitable Australian company that already operates in the relevant pharmaceutical sector.

The exporter discusses whether the company needs an additional qualified Indian manufacturer.

This may be a practical starting point because the Australian partner already understands the local regulatory and commercial environment.

However, the particular product and manufacturing site must still satisfy the applicable regulatory requirements.

An existing ARTG entry should not be assumed to cover a new manufacturer or a different product automatically.

Strategy 2: Develop a New Product with an Australian Sponsor

In this model, the exporter identifies a product opportunity and coordinates with a manufacturer and Australian sponsor.

The parties evaluate the feasibility of a new registration or other applicable market-entry pathway.

This approach may provide more control over product selection and long-term commercial arrangements.

However, it can involve significant upfront cost, regulatory work and uncertainty.

Startups should proceed only after receiving appropriate technical and commercial commitments.

Strategy 3: Become a Specialized Sourcing Partner

A startup may focus on supporting Australian companies with qualified Indian manufacturers, product research and commercial coordination.

Instead of funding registration independently, the exporter works with established pharmaceutical businesses seeking additional supply sources.

This model may reduce the need to finance every aspect of market entry.

However, it still requires supplier knowledge, reliable agreements and a clear commercial value proposition.

For a startup without substantial capital, building sourcing capabilities and relationships before investing in a new registration may be a practical approach.

Common Mistakes Indian Exporters Should Avoid

One common mistake is assuming that any medicine manufactured in India can be exported directly to an Australian distributor for commercial sale.

Another is believing that hiring an Australian sponsor automatically guarantees TGA approval.

Some exporters also confuse ARTG registration with PBS listing.

Others compare published PBS prices directly with their own factory quotations and assume that the difference represents profit.

Another mistake is agreeing to large registration expenses without understanding expected demand or contractual purchase commitments.

Some startups choose manufacturers with low prices but insufficient Australian regulatory documentation.

Others overlook the sponsor's ongoing responsibilities, such as pharmacovigilance, product complaints and regulatory maintenance.

These mistakes can create financial losses and regulatory difficulties.

A successful export strategy should address them before the first commercial shipment.

A Step-by-Step Roadmap for Indian Startups

Step 1: Select a Specific Pharmaceutical Product

Begin with one clearly identified active ingredient, strength and dosage form.

Avoid trying to enter the entire Australian pharmaceutical market at once.

Step 2: Understand the Therapeutic Category

Research the approved applications of the product and its commercial relevance.

Step 3: Search the ARTG

Identify existing products, sponsors and relevant regulatory information.

Step 4: Study the PBS

Examine whether the medicine is subsidised, the applicable product entries and relevant pricing arrangements.

Step 5: Examine Competition and Supply Gaps

Research established suppliers, medicine shortages where relevant and possible supply-chain requirements.

Step 6: Identify Qualified Indian Manufacturers

Request manufacturing details, technical documentation and information about Australian regulatory readiness.

Step 7: Evaluate the Registration Pathway

Understand whether the product requires a new ARTG application, changes to an existing entry or another applicable regulatory procedure.

Step 8: Identify Australian Sponsors and Distributors

Approach suitable companies with a relevant product-focused introduction.

Step 9: Obtain Commercial Feedback

Discuss product requirements, price expectations, expected volume and available market-access arrangements.

Step 10: Clarify Regulatory and Financial Responsibilities

Determine who will pay for regulatory activities and who will hold the relevant market authorization.

Step 11: Prepare a Complete Export Costing

Include manufacturer pricing, logistics, compliance contributions and other relevant commercial expenses.

Step 12: Negotiate the Business Agreement

Agree on payment terms, delivery responsibilities, supply commitments, exclusivity and other essential conditions.

Step 13: Complete the Required Regulatory Process

The appropriate Australian sponsor must obtain the necessary market authorization or use another lawful pathway where applicable.

Step 14: Arrange the Commercial Shipment

Once the product is legally eligible for commercial supply, coordinate shipment according to the approved product particulars and agreed contractual responsibilities.

Step 15: Maintain Long-Term Supply Relationships

Focus on product consistency, availability, appropriate documentation and communication with the Australian partner.

This is a structured business-development process, not a promise that registration or commercial orders can be completed within a particular number of days.

The actual timeline depends on the product and regulatory pathway.

Can Common Generic Medicines Become Profitable in Australia?

Many startups believe that only innovative, expensive or highly specialized medicines offer good export opportunities.

However, an established generic medicine may also have commercial value.

For example, an Australian distributor may already serve a market with ongoing demand for an approved generic medicine.

The distributor may want another qualified manufacturer to improve supply reliability.

An Indian merchant exporter who can arrange suitable documentation and dependable manufacturing may become a useful sourcing partner.

However, a common generic may also face intense competition and pricing pressure.

Therefore, the key is not simply to identify a widely used medicine.

It is to determine whether the proposed supply arrangement offers a meaningful commercial advantage.

That advantage might involve competitive production costs, reliable availability, suitable technical documentation or a well-structured long-term agreement.

The exporter must be able to demonstrate the advantage rather than merely claim it.

Why Reliable Supply Can Be More Valuable Than the Lowest Price

Imagine that an Australian distributor has two potential suppliers.

Supplier A offers a lower unit price but has uncertain delivery schedules.

Supplier B offers a slightly higher price but provides verified manufacturing documentation and a dependable supply plan.

The distributor may consider several factors before making a decision.

These include procurement cost, inventory risk, compliance requirements, continuity of supply and potential consequences of product shortages.

In a regulated pharmaceutical market, supply reliability can be an important part of the overall commercial value.

However, a higher price does not automatically mean better reliability.

The exporter must support its claims with actual manufacturing capabilities, lead-time records, quality systems and realistic contractual commitments.

This is where a knowledgeable merchant exporter can create value beyond ordinary product trading.

Final Thoughts: Australia's Pharma Market Rewards Preparation

Australia offers meaningful opportunities for Indian pharmaceutical manufacturers and merchant exporters.

India's pharmaceutical exports to Australia reached approximately USD 469.76 million in FY 2024–25, confirming that an established trade relationship already exists.

However, Australia is not a market where a startup can simply purchase medicines in India and immediately begin commercial sales.

The TGA and ARTG framework creates important product registration and regulatory requirements.

The PBS provides a separate system for subsidising eligible medicines and creates useful opportunities for market research.

Australian sponsors play a central legal role in bringing regulated products to the market.

For merchant exporters, the most practical opportunity may involve identifying a product, selecting a qualified Indian manufacturer and developing a suitable partnership with an established Australian sponsor or distributor.

It is also important to negotiate regulatory expenses, purchase commitments and long-term commercial responsibilities before making substantial investments.

Remember one important business principle:

A regulated pharmaceutical market may be more difficult to enter, but the right technical knowledge, regulatory preparation and reliable partnerships can help an Indian startup build a meaningful position in its supply chain.

For new entrepreneurs, the objective should not be to avoid every market with complicated compliance requirements.

Instead, the objective should be to understand those requirements and decide whether the commercial opportunity justifies the investment.

Australia is a market worth studying carefully.

Start with one product, verify its market position, understand the regulatory pathway, find suitable partners and proceed through a commercially responsible plan.

At Barai Overseas, we focus on helping Indian entrepreneurs understand international pharmaceutical markets, product selection, manufacturer sourcing, regulatory challenges and practical merchant-export opportunities.

Our educational approach encourages startups to develop real product knowledge and reliable international business relationships rather than depend only on general export marketing.

Watch Our Original Video

Australia Pharma Market: Opportunities & Challenges for Indian Exporters

https://www.youtube.com/watch?v=dk-QftWaKyE

For more pharmaceutical export-import learning resources, visit:

https://www.exportimport.guru/

Useful Official References